BI broadens research pact with Vanderbilt University to develop GPCR drugs for brain disorders
Boehringer Ingelheim has been working to boost its research capabilities in central nervous system (CNS) disorders, making moves over the past year aimed specifically at adding compounds to its pipeline to address Alzheimer’s disease (AD), schizophrenia and depression. Now it’s teaming up with Vanderbilt University, located in Nashville to develop novel small molecules that modulate brain circuits.
BI announced that the pact with Vanderbilt, which follows four cancer-focused research partnerships the two already have, will focus on compounds that target two different G-protein coupled receptors (GPCRs). The potential of targeting these receptors in a variety of CNS disorders has long been of interest to BI. Just last month, in fact, the company teamed up with Domain Therapeutics to develop GPCR drugs.